News

Low-Dose Radiation Leads To Drop In PAR For Idiopathic Pulmonary Arterial Hypertension Patient, According To Study

A novel concept of targeting the autonomic nervous system around pulmonary arteries and activation of vasointestinal peptides (VIP) to treat Idiopathic Pulmonary Arterial Hypertension (IPAH) was recently developed by a group of researchers. The study, published in the online journal Therapeutics and Clinical Risk Management (March 27, 2014), profiled a 58…

Early-Stage Pulmonary Arterial Hypertension Therapy From Pulmokine Awarded $1.5 Million Through Federally Funded VITA Contract

Rensselaer, New York-based biopharmaceutical company Pulmokine recently made a major announcement regarding the company’s efforts in developing a novel therapy for pulmonary arterial hypertension (PAH). In a press release from late March, Pulmokine indicated that that the National Heart, Lung, and Blood Institute (NHLBI), a division of the federally run National…

Pulmonary Arterial Hypertension, CTEPH Treatment Adempas Gets European Commission Approval

Among the fives types of PH, Pulmonary Arterial Hypertension (PAH) is recognized as a serious unmet medical need in terms of viable treatments, due to the progressive and life-threatening characteristics of the disease.  PAH patients experience symptoms where blood pressure in the pulmonary arteries is significantly heightened due to vasoconstriction, frequently…